Specialty pharma OptiNose hopes to use up to $30 million in new financing to get its OPN-375 in combination with its novel breath-powered device through the FDA. But the agency already demonstrated some skepticism around the device last year--it issued a complete response letter to OptiNose partner Avanir because of device errors and required further testing.
Venture-backed Ark Biosciences has successfully completed a Phase I clinical trial of work on anti-respiratory syncytial virus (RSV) candidate AK0529, hitting a key milestone for the respiratory viral infection and viral hepatitis focused company.
GlaxoSmithKline now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012.
As part of its so-called Base Plus Plus Plus strategy, specialty pharmaceutical company Perrigo announced that it is licensing Flamel's LiquiTime extended-release suspension to develop products for the U.S. over-the-counter market.
Regeneron is handing off the Asian rights to its in-development musculoskeletal pain treatment for up to $325 million, handing the antibody over to a subsidiary of Japanese giant Mitsubishi.
Illumina is joining forces with China's Amoy Diagnostics to create next-generation sequencing cancer tests for the Chinese clinical market, expanding its footprint in the country while strengthening its commitment to developing innovative technology for the disease.
Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.
PRA Health Sciences has joined forces with a trial site group to focus on vaccine development, hoping to speed up patient recruitment and get more clinical studies rolling.
China clinical-stage biotech CARsgen signed a 5-year partnership agreement with the Shanghai Cancer Institute to develop CARsgen's chimeric antigen receptor T-cell immunotherapeutics.
Quest Diagnostics has been working hard to diversify its offerings, beefing up its presence in diagnostics as it delivers on plans for growth. In its latest move, the company is teaming up with health IT outfit Inovalon to roll out a cloud-based analytics platform for healthcare providers.